ORTX Orchard Therapeutics plc ADRs
Orchard Therapeutics plc, an integrated biopharmaceutical company, focuses on developing various transformative treatments. It dedicated to transform the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company, formerly known as Orchard Rx Limited, was founded in 2015 and is headquartered in London, the United Kingdom. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$4.72 -0.19 (-3.87%)
As of 03/27/2023 14:06:39 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: United Kingdom
Country of incorporation:
IPO date: 10/31/2018
Outstanding shares: 183,984,499
Average volume: 122,682
Market cap: $942,000,635
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol: BGT3960
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%